Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
← catalyst calendarNCT05201638 · readout ≤ 103 d
Sponsored by Immunic AG (industry) · IMUX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,100actual
Sites
76
Countries
Armenia, Bosnia and Herzegovina, Estonia +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-12 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis, Relapsing-Remitting
Interventions
- Drug: IMU-838 tablets — also filed as Vidofludimus calcium
- Drug: Placebo matching IMU-838 tablets — also filed as Placebo matching vidofludimus calcium
Primary outcome
what the primary-completion date above is the date OFTo evaluate efficacy of IMU-838 versus placebo based on time to first relapse
measured 72 weeks
Permalink · IMUX's whole pipeline · Catalyst calendar · Every registered study · What changed